JP2018504105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504105A5 JP2018504105A5 JP2017533597A JP2017533597A JP2018504105A5 JP 2018504105 A5 JP2018504105 A5 JP 2018504105A5 JP 2017533597 A JP2017533597 A JP 2017533597A JP 2017533597 A JP2017533597 A JP 2017533597A JP 2018504105 A5 JP2018504105 A5 JP 2018504105A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr2
- cdr3
- cdr1
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 32
- 108090001123 antibodies Proteins 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 17
- 102000038129 antigens Human genes 0.000 claims 17
- 108091007172 antigens Proteins 0.000 claims 17
- 229920000023 polynucleotide Polymers 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 230000000295 complement Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003445 Biliary Tract Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 210000004696 Endometrium Anatomy 0.000 claims 1
- 210000003238 Esophagus Anatomy 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 210000000867 Larynx Anatomy 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 210000003739 Neck Anatomy 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 210000000664 Rectum Anatomy 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
Claims (27)
- ヒトMerチロシンキナーゼ(MERTK)に特異的に結合する抗体またはその抗原結合フラグメントであって、前記抗体は、重鎖可変領域(VH)および軽鎖可変領域(VL)を含み、この際
(i)前記VHは、配列番号1の相補的決定領域(CDR)1、配列番号6のCDR2、及び配列番号11のCDR3を含み、前記VLは、配列番号15のCDR1、配列番号19のCDR2、及び配列番号22のCDR3を含む、;
(ii)前記VHは、配列番号2のCDR1、配列番号7のCDR2、及び配列番号12のCDR3を含み、前記VLは、配列番号16のCDR1、配列番号20のCDR2、及び配列番号23のCDR3を含む;
(iii)前記VHは、配列番号3のCDR1、配列番号8のCDR2、及び配列番号11のCDR3を含み、前記VLは、配列番号15のCDR1、配列番号19のCDR2、及び配列番号22のCDR3を含む、;
(iv)前記VHは、配列番号4のCDR1、配列番号9のCDR2、及び配列番号13のCDR3を含み、前記VLは、配列番号17のCDR1、配列番号21のCDR2、及び配列番号24のCDR3を含む;
(v)前記VHは、配列番号5のCDR1、配列番号10のCDR2、及び配列番号14のCDR3を含み、前記VLは、配列番号18のCDR1、配列番号20のCDR2、及び配列番号22のCDR3を含む;
(vi)前記VHは、配列番号3のCDR1、配列番号6のCDR2、及び配列番号11のCDR3を含み、前記VLは、配列番号15のCDR1、配列番号19のCDR2、及び配列番号22のCDR3を含む;
(vii)前記VHは、配列番号25のCDR1、配列番号30のCDR2、及び配列番号35のCDR3を含み、前記VLは、配列番号39のCDR1、配列番号43のCDR2、及び配列番号46のCDR3を含む;
(viii)前記VHは、配列番号26のCDR1、配列番号31のCDR2、及び配列番号36のCDR3を含み、前記VLは、配列番号40のCDR1、配列番号44のCDR2、及び配列番号47のCDR3を含む;
(ix)前記VHは、配列番号27のCDR1、配列番号32のCDR2、及び配列番号35のCDR3を含み、前記VLは、配列番号39のCDR1、配列番号43のCDR2、及び配列番号46のCDR3を含む;
(x)前記VHは、配列番号28のCDR1、配列番号33のCDR2、及び配列番号37のCDR3を含み、前記VLは、配列番号41のCDR1、配列番号45のCDR2、及び配列番号48のCDR3を含む;
(xi)前記VHは、配列番号29のCDR1、配列番号34のCDR2、及び配列番号38のCDR3を含み、前記VLは、配列番号42のCDR1、配列番号44のCDR2、及び配列番号46のCDR3を含む;または
(xii)前記VHは、配列番号27のCDR1、配列番号30のCDR2、及び配列番号35のCDR3を含み、前記VLは、配列番号39のCDR1、配列番号43のCDR2、及び配列番号46のCDR3を含む、抗体またはその抗原結合フラグメント。 - (i)前記VHは、配列番号1の相補的決定領域(CDR)1、配列番号6のCDR2、及び配列番号11のCDR3を含み、前記VLは、配列番号15のCDR1、配列番号19のCDR2、及び配列番号22のCDR3を含む、;
(ii)前記VHは、配列番号2のCDR1、配列番号7のCDR2、及び配列番号12のCDR3を含み、前記VLは、配列番号16のCDR1、配列番号20のCDR2、及び配列番号23のCDR3を含む;
(iii)前記VHは、配列番号3のCDR1、配列番号8のCDR2、及び配列番号11のCDR3を含み、前記VLは、配列番号15のCDR1、配列番号19のCDR2、及び配列番号22のCDR3を含む、;
(iv)前記VHは、配列番号4のCDR1、配列番号9のCDR2、及び配列番号13のCDR3を含み、前記VLは、配列番号17のCDR1、配列番号21のCDR2、及び配列番号24のCDR3を含む;
(v)前記VHは、配列番号5のCDR1、配列番号10のCDR2、及び配列番号14のCDR3を含み、前記VLは、配列番号18のCDR1、配列番号20のCDR2、及び配列番号22のCDR3を含む;または
(vi)前記VHは、配列番号3のCDR1、配列番号6のCDR2、及び配列番号11のCDR3を含み、前記VLは、配列番号15のCDR1、配列番号19のCDR2、及び配列番号22のCDR3を含む、請求項1に記載の抗体またはその抗原結合フラグメント。 - (vii)前記VHは、配列番号25のCDR1、配列番号30のCDR2、及び配列番号35のCDR3を含み、前記VLは、配列番号39のCDR1、配列番号43のCDR2、及び配列番号46のCDR3を含む;
(viii)前記VHは、配列番号26のCDR1、配列番号31のCDR2、及び配列番号36のCDR3を含み、前記VLは、配列番号40のCDR1、配列番号44のCDR2、及び配列番号47のCDR3を含む;
(ix)前記VHは、配列番号27のCDR1、配列番号32のCDR2、及び配列番号35のCDR3を含み、前記VLは、配列番号39のCDR1、配列番号43のCDR2、及び配列番号46のCDR3を含む;
(x)前記VHは、配列番号28のCDR1、配列番号33のCDR2、及び配列番号37のCDR3を含み、前記VLは、配列番号41のCDR1、配列番号45のCDR2、及び配列番号48のCDR3を含む;
(xi)前記VHは、配列番号29のCDR1、配列番号34のCDR2、及び配列番号38のCDR3を含み、前記VLは、配列番号42のCDR1、配列番号44のCDR2、及び配列番号46のCDR3を含む;または
(xii)前記VHは、配列番号27のCDR1、配列番号30のCDR2、及び配列番号35のCDR3を含み、前記VLは、配列番号39のCDR1、配列番号43のCDR2、及び配列番号46のCDR3を含む、請求項1に記載の抗体またはその抗原結合フラグメント。 - (A)(i)配列番号51のアミノ酸配列を含む重鎖可変領域および(ii)配列番号52のアミノ酸配列を含む軽鎖可変領域;または
(B)(i)配列番号49のアミノ酸配列を含む重鎖可変領域および(ii)配列番号50のアミノ酸配列を含む軽鎖可変領域、を含む、請求項1〜3のいずれか1項に記載の抗体またはその抗原結合フラグメント。 - ヒト由来定常領域を含む、請求項1〜4のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- ヒト化されている、請求項1〜3のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- モノクローナル抗体またはその抗原結合断片である、請求項1〜4のいずれかに記載の抗体またはその抗原結合フラグメント。
- 精製されている、請求項1〜7のいずれかに記載の抗体またはその抗原結合フラグメント。
- 請求項1〜8のいずれかに記載の抗体またはその抗原結合フラグメントをコードするポリヌクレオチドを含む、単離核酸。
- 請求項1〜8のいずれかに記載の抗体またはその抗原結合フラグメントをコードする1つ以上のポリヌクレオチドを含む、エクスビボ細胞。
- 前記1つ以上のポリヌクレオチドが前記エクスビボ細胞によって発現して、前記抗体または抗原結合フラグメントを産生するような条件下で、請求項10に記載のエクスビボ細胞を培養することを含む、抗体または抗原結合フラグメントを産生する方法。
- 治療有効量の請求項1〜8のいずれかに記載の抗体または抗原結合フラグメントと、医薬的に許容される担体とを含む、医薬組成物。
- 請求項1〜8のいずれかに記載の抗体を含む、ヘテロ共役抗体。
- 治療有効量の請求項13に記載のヘテロ共役抗体と、医薬的に許容される担体とを含む、医薬組成物。
- 請求項1〜8のいずれかに記載の抗体または抗原結合フラグメントの抱合体を含む、キット。
- 請求項1〜8のいずれかに記載の抗体もしくは抗原結合フラグメントまたは請求項13に記載のヘテロ共役抗体を含む、癌治療用医薬組成物。
- 前記癌は、肺、胸、骨、卵巣、胃、膵臓、喉頭、食道、精巣、肝臓、耳下腺、胆道、結腸、直腸、頸、子宮、子宮内膜、腎臓、膀胱、前立腺、または甲状腺の癌である、請求項16に記載の医薬組成物。
- 前記癌は、乳癌である、請求項16に記載の医薬組成物。
- 前記癌は、トリプルネガティブ乳癌である、請求項16に記載の医薬組成物。
- 抗体重鎖であって、前記重鎖は、
(A)配列番号1のVH CDR1、配列番号6のVH CDR2、及び配列番号11のVH CDR3、
(B)配列番号2のVH CDR1、配列番号7のVH CDR2、及び配列番号12のVH CDR3、
(C)配列番号3のVH CDR1、配列番号8のVH CDR2、及び配列番号11のVH CDR3、
(D)配列番号4のVH CDR1、配列番号9のVH CDR2、及び配列番号13のVH CDR3、
(E)配列番号5のVH CDR1、配列番号10のVH CDR2、及び配列番号14のVH CDR3、
(F)配列番号3のVH CDR1、配列番号6のVH CDR2、及び配列番号11のVH CDR3、を含む、抗体重鎖。 - 抗体軽鎖であって、前記軽鎖は、
(A)配列番号15の軽鎖可変領域(VL)CDR1、配列番号19のVL CDR2、及び配列番号22のVL CDR3、
(B)配列番号16のVL CDR1、配列番号20のVL CDR2、及び配列番号23のVL CDR3、
(C)配列番号17のVL CDR1、配列番号21のVL CDR2、及び配列番号24のVL CDR3、
(D)配列番号18のVL CDR1、配列番号20のVL CDR2、及び配列番号22のVL CDR3、を含む、抗体軽鎖。 - 抗体重鎖であって、前記重鎖は、
(A)配列番号25のVH CDR1、配列番号30のVH CDR2、及び配列番号35のVH CDR3、
(B)配列番号26のVH CDR1、配列番号31のVH CDR2、及び配列番号36のVH CDR3、
(C)配列番号27のVH CDR1、配列番号32のVH CDR2、及び配列番号35のVH CDR3、
(D)配列番号28のVH CDR1、配列番号33のVH CDR2、及び配列番号37のVH CDR3、
(E)配列番号29のVH CDR1、配列番号34のVH CDR2、及び配列番号38のVH CDR3、または
(F)配列番号27のVH CDR1、配列番号30のVH CDR2、及び配列番号35のVH CDR3、を含む、抗体重鎖。 - 抗体軽鎖であって、前記軽鎖は、
(A)配列番号39のVL CDR1、配列番号43のVL CDR2、及び配列番号46のVL CDR3、
(B)配列番号40のVL CDR1、配列番号44のVL CDR2、及び配列番号47のVL CDR3、
(C)配列番号41のVL CDR1、配列番号45のVL CDR2、及び配列番号48のVL CDR3、または
(D)配列番号42のVL CDR1、配列番号44のVL CDR2、及び配列番号46のVL CDR3、を含む、抗体軽鎖。 - 請求項20または22に記載の抗体重鎖をコードするポリヌクレオチドを含む、単離核酸。
- 請求項20または22に記載の抗体重鎖をコードするポリヌクレオチドを含有する、エクスビボ細胞。
- 請求項21または23に記載の抗体軽鎖をコードするポリヌクレオチドを含む、単離核酸。
- 請求項21または23に記載の抗体軽鎖をコードするポリヌクレオチドを含有する、エクスビボ細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462095325P | 2014-12-22 | 2014-12-22 | |
US62/095,325 | 2014-12-22 | ||
PCT/US2015/067118 WO2016106221A1 (en) | 2014-12-22 | 2015-12-21 | Anti-mertk agonistic antibodies and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018504105A JP2018504105A (ja) | 2018-02-15 |
JP2018504105A5 true JP2018504105A5 (ja) | 2019-02-07 |
JP7211703B2 JP7211703B2 (ja) | 2023-01-24 |
Family
ID=56151490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017533597A Active JP7211703B2 (ja) | 2014-12-22 | 2015-12-21 | 抗mertkアゴニスト抗体及びその使用 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10221248B2 (ja) |
EP (2) | EP3789039A1 (ja) |
JP (1) | JP7211703B2 (ja) |
CA (1) | CA2972048C (ja) |
ES (1) | ES2862701T3 (ja) |
HK (1) | HK1245807A1 (ja) |
WO (1) | WO2016106221A1 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016049641A1 (en) * | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
WO2019005756A1 (en) * | 2017-06-28 | 2019-01-03 | The Rockefeller University | CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE |
WO2019084307A1 (en) * | 2017-10-26 | 2019-05-02 | Celldex Therapeutics, Inc. | ANTI-MERTK ANTIBODIES AND METHODS OF USE |
CR20200303A (es) | 2017-12-12 | 2020-12-23 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y métodos relacionados |
IT201800000535A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
WO2019201970A1 (en) | 2018-04-19 | 2019-10-24 | University Of Copenhagen | A mertk ligand for adoptive t cell cancer therapy |
JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
CN112888445A (zh) | 2018-08-30 | 2021-06-01 | Hcw生物科技公司 | 治疗老年化相关病症的方法 |
JP2022512642A (ja) * | 2018-10-09 | 2022-02-07 | ブリストル-マイヤーズ スクイブ カンパニー | がんを治療するための抗MerTK抗体 |
WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
CA3130303A1 (en) * | 2019-02-26 | 2020-09-03 | Rgenix, Inc. | High-affinity anti-mertk antibodies and uses thereof |
MX2021012692A (es) * | 2019-04-19 | 2021-11-12 | Genentech Inc | Anticuerpos anti-mertk y sus metodos de uso. |
WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
IL293827A (en) * | 2019-12-13 | 2022-08-01 | Alector Llc | Anti-mertko antibodies and methods of using them |
WO2021142086A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
IL295084A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Chromatography resin and its uses |
AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
IL295083A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods for activating regulatory t cells |
WO2021202590A1 (en) * | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods for treating disorders related to aging |
JP2024519333A (ja) * | 2021-05-14 | 2024-05-10 | インスピアーナ, インコーポレイテッド | Mertkペプチドおよびその使用 |
EP4355786A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2024022495A1 (en) * | 2022-07-28 | 2024-02-01 | Concept To Medicine Biotech Co., Ltd. | Anti-MerTK ANTIBODIES AND USES THEREOF |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569A (en) | 1848-05-16 | Corn-sheller | ||
US825A (en) | 1838-07-09 | Bail way cooking-stove | ||
US985317A (en) | 1910-07-11 | 1911-02-28 | Julius R W Anderson | Clam-shell bucket. |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
ATE243745T1 (de) | 1994-01-31 | 2003-07-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6027947A (en) | 1996-08-20 | 2000-02-22 | Ramtron International Corporation | Partially or completely encapsulated top electrode of a ferroelectric capacitor |
US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
NZ334914A (en) | 1996-10-01 | 2000-09-29 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
EP0968291B1 (en) * | 1997-02-21 | 2004-01-28 | Genentech, Inc. | Antibody fragment-polymer conjugates |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
RU2224766C2 (ru) | 1997-04-14 | 2004-02-27 | Микромет Аг | Способ получения рецепторов для человеческих антигенов и их применение |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
WO1999021537A1 (fr) | 1997-10-28 | 1999-05-06 | Bando Chemical Industries, Ltd. | Feuille de timbre cutane et procede de production d'une feuille de base pour timbre |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
DK1233987T3 (da) | 1999-11-29 | 2009-09-28 | Bac Ip B V | Immobiliserede enkelt-domæne antigenbindende molekyler |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
EP1825005B1 (en) * | 2004-11-24 | 2015-07-15 | The Regents of the University of Colorado, a body corporate | Mer diagnostic and therapeutic agents |
JP2006315964A (ja) * | 2005-05-10 | 2006-11-24 | Chugai Pharmaceut Co Ltd | 抗体安定化方法 |
CA2960659C (en) | 2007-11-09 | 2021-07-13 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
MX2011014008A (es) | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
AU2011291450B2 (en) * | 2010-08-19 | 2015-05-14 | Howard Florey Institute | TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease |
US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
TWI777174B (zh) * | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
-
2015
- 2015-12-21 EP EP20201416.3A patent/EP3789039A1/en active Pending
- 2015-12-21 ES ES15874253T patent/ES2862701T3/es active Active
- 2015-12-21 JP JP2017533597A patent/JP7211703B2/ja active Active
- 2015-12-21 US US15/538,510 patent/US10221248B2/en active Active
- 2015-12-21 WO PCT/US2015/067118 patent/WO2016106221A1/en active Application Filing
- 2015-12-21 CA CA2972048A patent/CA2972048C/en active Active
- 2015-12-21 EP EP15874253.6A patent/EP3237450B1/en active Active
-
2018
- 2018-04-19 HK HK18105107.9A patent/HK1245807A1/zh unknown
-
2019
- 2019-01-24 US US16/256,737 patent/US11225524B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018504105A5 (ja) | ||
JP2019054802A5 (ja) | ||
JP2020510422A5 (ja) | ||
JP2014526898A5 (ja) | ||
JP2019535254A5 (ja) | 抗pd−l1抗体および変異型 | |
JP2015535828A5 (ja) | ||
JP2017149720A5 (ja) | ||
JP2018505681A5 (ja) | ||
JP2013538057A5 (ja) | ||
RU2017105915A (ru) | Антитела против pd-1 | |
RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
JP2010526028A5 (ja) | ||
JP2009225799A5 (ja) | ||
JP2013506428A5 (ja) | ||
RU2016100892A (ru) | Антитела против tweakr и их применение | |
RU2019118257A (ru) | Анти-cd47 антитела и способы их применения | |
JP2011505146A5 (ja) | ||
JP2016523810A5 (ja) | ||
JP2016526904A5 (ja) | ||
JP2016516400A5 (ja) | ||
JP2008508858A5 (ja) | ||
JP2017512759A5 (ja) | ||
JP2020502271A5 (ja) | ||
JP2014205674A5 (ja) | ||
JP2015506912A5 (ja) |